MARKET

ASMB

ASMB

Assembly
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.060
-0.110
-2.64%
Pre Market: 4.065 +0.005 +0.12% 09:09 06/21 EDT
OPEN
4.160
PREV CLOSE
4.170
HIGH
4.180
LOW
4.040
VOLUME
12.32K
TURNOVER
--
52 WEEK HIGH
27.84
52 WEEK LOW
3.780
MARKET CAP
163.04M
P/E (TTM)
-2.3812
1D
5D
1M
3M
1Y
5Y
The Week Ahead In Biotech: Incyte, Ascendis FDA Decisions, Liver Congress Presentations And 4 IPOs
Biotech stocks came under pressure in the week ended June 18, dragged by the negative sentiment that prevailed in the broader market due to macroeconomic worries.
Benzinga · 23h ago
Assembly Biosciences to Present Data from HBV Core Inhibitor Programs at The International Liver Congress(TM) EASL 2021
Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV), today announced that three abstracts have been accepted for presentation during the International Liver ...
GlobeNewswire · 06/09 12:00
Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV), today announced grants of stock options to six new employees to purchase an aggregate of 106,520 shares ...
GlobeNewswire · 06/04 21:00
Assembly Biosciences announces resignation of CFO
The chief financial officer of Assembly Biosciences ([[ASMB]] -1.5%) Thomas J. Russo is leaving the company, the company said in a regulatory filing yesterday.Mr. Russo who also served the company as
Seekingalpha · 06/02 13:56
BRIEF-Assembly Biosciences Says CFO Thomas Russo To Resign Effective June 4
reuters.com · 06/01 21:09
The Daily Biotech Pulse: Vir-GlaxoSmithKline COVID-19 Antibody Treatment Approved, Zosano Spikes On Long-Term Migraine Drug Data, Decision Day For Eton, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 26)
Benzinga · 05/27 12:24
Stocks That Hit 52-Week Lows On Wednesday
    Wednesday morning, 20 companies set new 52-week lows.
Benzinga · 05/26 17:24
BRIEF-Lisa Johnson-Pratt Joins Assembly Biosciences Board Of Directors
reuters.com · 05/24 12:28
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ASMB. Analyze the recent business situations of Assembly through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ASMB stock price target is 10.95 with a high estimate of 15.00 and a low estimate of 4.750.
EPS
Institutional Holdings
Institutions: 154
Institutional Holdings: 30.79M
% Owned: 76.67%
Shares Outstanding: 40.16M
TypeInstitutionsShares
Increased
38
3.58M
New
15
2.34M
Decreased
34
1.48M
Sold Out
16
2.79M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-1.19%
Pharmaceuticals & Medical Research
-0.98%
Key Executives
Non-Executive Chairman/Independent Director
William Ringo
President/Chief Executive Officer/Director
John McHutchison
Chief Financial Officer
Thomas Russo
Chief Financial Officer
Thomas Joseph Russo
Chief Financial Officer
Michael Samar
Senior Vice President
Nicole White
Chief Scientific Officer
William Delaney
Other
Jason Okazaki
Other
Luisa Stamm
Director
Lisa Johnson-Pratt
Independent Director
Anthony Altig
Independent Director
Gina Consylman
Independent Director
Richard DiMarchi
Independent Director
Myron Holubiak
Independent Director
Susan Mahony
No Data
About ASMB
Assembly Biosciences, Inc. is a biotechnology company. The Company is engaged in developing two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral synthetic live therapeutics, which are designed to restore health to a dysbiotic microbiome. It has discovered various core protein Allosteric Modulators (CpAMs), which are small molecules that directly target and allosterically modulate the HBV core (HBc) protein. Its Microbiome Program consists of an integrated platform that includes a strain identification and selection process, methods for strain isolation and growth under current good manufacturing practice conditions, and a delivery system, GEMICEL, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal (GI) tract. The lead product candidate from this platform, AB-M101, is in development for the treatment of clostridium difficile-infections.

Webull offers kinds of Assembly Biosciences Inc stock information, including NASDAQ:ASMB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ASMB stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ASMB stock methods without spending real money on the virtual paper trading platform.